{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
histamine
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (MIXED)
Pyroxamine (also known as AHR 224) is benzhydryl ethers of 3-pyrrolidinol patented by A. H. Robins Co., Inc. as antihistamine with bronchodilation activity. In preclinical studies, Pyroxamine shows moderate inhibition of histamine-induced ulceration in guinea pigs
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Amoxydramine is tertiary dialkylarylcarbinol derivative patented by American chemical company Allied Chemical Corp as an antitussive, sedative, and antihypertensive agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Diethazine is the antimuscarinic agent. It has actions similar to those of ethopropazine but it is more toxic. Diethazine is used for the palliative treatment of the parkinsonian syndrome. It is more useful in the treatment of Parkinson’s disease than in allergies. Blockade of single contractions observed in these experiments after administration of diethazine was independent of the frequency of stimulation of the nerve. This suggests that the drug acts directly on the postsynaptic receptor in the endplate.
Status:
Investigational
Source:
INN:methiomeprazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Vapitadine (R129160; Hivenyl™) is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. Vapitadine is a new selective, non-sedative H1antihistamine. In several in vitro and in vivo pharmacological models, vapitadine is at least as potent as cetirizine (Zyrtec®) and does not penetrate the blood-brain barrier. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses. Vapitadine had been in phase II clinical trials for the treatment of patients with atopic dermatitis. However, no development has been reported.
Status:
Investigational
Source:
INN:sulfonterol [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Sulfonterol is a benzenemethanol derivative patented by Smith Kline and French Laboratories as a bronchodilator. Sulfonterol acts as a β-adrenergic partial agonist.
Status:
Investigational
Source:
NCT01006122: Phase 2 Interventional Completed Excessive Daytime Sleepiness
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
PF-03654746 is a potent, selective antagonist of the human H3 receptor, developed by Pfizer. It was in the clinical trial phase II for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy, Tourette syndrome as well as potential anti-allergy applications and in phase I of clinical trial for the treatment of Schizophrenia and Alzheimer's disease, but these investigations were discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Efletirizine is histamine H1 receptor antagonist. Restricted to topical use. It was under investigation in Phase III (in Europe) clinical studies for the treatment of allergic rhinitis and chronic idiopathic urticarial. Research was discontinued in 2005 due to limited clinical efficacy and safety data. Efletirizine also reduced ocular itching.
Class (Stereo):
CHEMICAL (ACHIRAL)
Nemazoline (A-57219) is a nasal decongestant. It has alpha 1-agonist/alpha 2-antagonist activity and was more effective and long-acting than oxymetazoline on canine nasal mucosa, in-vitro and in-vivo. Upon intranasal administration to dogs, the compound was devoid of systemic effects up to a concentration 1000 times that needed for local decongestant effect (1.65 micrograms, atomized from a 1 microgram mL-1 solution) suggesting limited mucosal absorption. After nasal administration to rats for 15 days at a concentration 1000 times greater than that required for nasal decongestion, no mucosal tissue toxicity or systemic effects were seen.
Class (Stereo):
CHEMICAL (ACHIRAL)
Phenamazoline is an antazoline derivative. It is a sympathomimetic agent. It was developed as vasoconstrictor but its carbon analog is a vasodilator.
